The Quiet Outperformance of Recent Biotech IPOs

Biotech IPOs have long been viewed with skeptism, especially over the past few years in comparison to the high-flying media darlings in the Tech space. But recently a number of the social media phenoms have fallen from grace: Groupon is off 72%, Zynga is off 68%, and Facebook is off 44% as of today. Yet during the past 12-18 months, new Biotech IPOs have quietly been putting points on the board with their post-IPO performance. It’s now fair to say they have resoundingly outperformed their Tech cousins in the public markets.

Back to news